Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ENPP3 | O14638 | 3/20 | 0.34 |
| ▸ | ALPL | P05186 | 3/20 | 0.34 |
| ▸ | XIAP | P98170 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2956208 | 0.83 | TSHR (0.40) | ALDH1A1TSHRMEN1CYP1A2CYP3A4 | |
| SCHEMBL2961171 | 0.80 | FAAH (0.40) | ALDH1A1SMN1; SMN2TSHRMEN1CYP1A2 | |
| SCHEMBL6049124 | 0.76 | TSHR (0.39) | ALDH1A1SMN1; SMN2TSHRMEN1CYP1A2 | |
| SCHEMBL1531410 | 0.69 | MAPT (0.47) | ALDH1A1SMN1; SMN2GAATSHRMEN1 | |
| SCHEMBL1531077 | 0.68 | KMT2A (0.38) | ALDH1A1SMN1; SMN2GAATSHRMEN1 | |
| SCHEMBL18467794 | 0.67 | — | — | |
| SCHEMBL25293276 | 0.65 | ALDH1A1 (0.55) | ALDH1A1GAATSHRCYP1A2CYP3A4 | |
| SCHEMBL22692279 | 0.65 | KDM4E (0.39) | ALDH1A1SMN1; SMN2GAAMAPK1KDM4E | |
| SCHEMBL173200 | 0.63 | — | — | |
| SCHEMBL31695385 | 0.63 | LPO (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767827-B2 | Pyrazole-1-carboxylate derivatives, process for the production thereof and process for the production of pyrazole derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-7767827-B2 | Pyrazole-1-carboxylate derivatives, process for the production thereof and process for the production of pyrazole derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-7767827-B2 | Pyrazole-1-carboxylate derivatives, process for the production thereof and process for the production of pyrazole derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090018345-A1 | PYRAZOLE-1-CARBOXYLATE DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND PROCESS FOR THE PRODUCTION OF PYRAZOLE DERIVATIVES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20090018345-A1 | PYRAZOLE-1-CARBOXYLATE DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND PROCESS FOR THE PRODUCTION OF PYRAZOLE DERIVATIVES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20090018345-A1 | PYRAZOLE-1-CARBOXYLATE DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND PROCESS FOR THE PRODUCTION OF PYRAZOLE DERIVATIVES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| EP-1884512-A1 | PYRAZOLE-1-CARBOXYLIC ESTER DERIVATIVE, METHOD FOR PRODUCING THE SAME AND METHOD FOR PRODUCING PYRAZOLE DERIVATIVE | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2008-02-06 | — | — | EP | disclosed |
| EP-1884512-A1 | PYRAZOLE-1-CARBOXYLIC ESTER DERIVATIVE, METHOD FOR PRODUCING THE SAME AND METHOD FOR PRODUCING PYRAZOLE DERIVATIVE | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2008-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018345-A1 | PYRAZOLE-1-CARBOXYLATE DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND PROCESS FOR THE PRODUCTION OF PYRAZOLE DERIVATIVES | WEE1, CYP51A1, CYP4B1 | ALDH1A1 57/4885SMN1; SMN2 4836/4885GAA 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.